Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Accumulated Expenses (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Accumulated Expenses for 3 consecutive years, with $29000.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Accumulated Expenses rose 7.41% year-over-year to $29000.0, compared with a TTM value of $29000.0 through Sep 2024, up 7.41%, and an annual FY2023 reading of $605000.0, up 2780.95% over the prior year.
  • Accumulated Expenses was $29000.0 for Q3 2024 at Oramed Pharmaceuticals, roughly flat from $29000.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $605000.0 in Q4 2023 and bottomed at $21000.0 in Q4 2022.
  • Average Accumulated Expenses over 3 years is $109571.4, with a median of $29000.0 recorded in 2024.
  • The sharpest move saw Accumulated Expenses soared 2780.95% in 2023, then increased 7.41% in 2024.
  • Year by year, Accumulated Expenses stood at $21000.0 in 2022, then skyrocketed by 2780.95% to $605000.0 in 2023, then plummeted by 95.21% to $29000.0 in 2024.
  • Business Quant data shows Accumulated Expenses for ORMP at $29000.0 in Q3 2024, $29000.0 in Q2 2024, and $29000.0 in Q1 2024.